Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young patients aged 18-50 years inclusive or Elderly patients aged 65 years and over~* Patients must have a confirmed diagnosis of ET.~* Currently receiving anagrelide hydrochloride at a stable maintenance dose \< 5 mg/day for at least 4 weeks.~Exclusion Criteria:~* Diagnosis of any other myeloproliferative disorder.~* Current use of tobacco in any form (e.g. smoking or chewing)~* Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.~* Patients for whom use of another cytoreductive agent in addition to anagrelide is considered necessary for control of platelet count.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Younger Participants (18-50 years) (Type: EXPERIMENTAL): None
- Elderly Participants (≥65 years) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).